Algernon Pharmaceuticals Inc.
OTC: AGNPF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Christopher J. Moreau
- Employees
- 5
- Headquarters
- Vancouver, Canada
- IPO year
- 2016
- Market cap
- $879.0K
- Website
- https://algernonpharmaceuticals.com
Loading AGNPF…
Loading profile data…Frequently asked questions about AGNPF
What does Algernon Pharmaceuticals Inc. (AGNPF) do?
Algernon Pharmaceuticals Inc. is a biopharmaceutical firm actively engaged in drug development at the clinical trial stage. Its therapeutic endeavors span a range of challenging medical conditions, including non-alcoholic steatohepatitis (NASH), chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF),...
Where does AGNPF trade?
Algernon Pharmaceuticals Inc. (AGNPF) trades on the Other OTC.
What sector is AGNPF in?
Algernon Pharmaceuticals Inc. (AGNPF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Algernon Pharmaceuticals Inc.?
Christopher J. Moreau is the chief executive officer of Algernon Pharmaceuticals Inc. (AGNPF).
Where is Algernon Pharmaceuticals Inc. headquartered?
Algernon Pharmaceuticals Inc. is headquartered in Canada.
Does AGNPF pay a dividend?
Algernon Pharmaceuticals Inc. (AGNPF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did AGNPF go public?
Algernon Pharmaceuticals Inc. (AGNPF) completed its initial public offering in 2016.